Efficacy and safety of certolizumab pegol therapy for 26 weeks in an unselected Crohn's disease population: Results of the FACTS II survey
SR Vavricka, A Schöpfer, G Bansky, J Binek, C Felley, M Geyer, M Manz, G Rogler, P de Saussure, B Sauter, M Scharl, F Seibold, A Straumann, P Michetti · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and Aims: Certolizumab pegol (Cimzia CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients. Methods: Evaluation questionnaires at baseline, week 6 and 26 were completed by gastroenterologists in hospitals and private practices. Adverse events were evaluated according to WHO guidelines. Results: Sixty patients (38F/22M) were included, 53% had complicated disease (stricturing or penetrating), 45…
